HC Wainwright & Co. Reiterates Buy on Immix Biopharma, Maintains $7 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Robert Burns has reiterated a Buy rating on Immix Biopharma (NASDAQ:IMMX) and maintained a $7 price target.

July 26, 2024 | 11:00 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Robert Burns has reiterated a Buy rating on Immix Biopharma and maintained a $7 price target.
The reiteration of a Buy rating and the maintenance of a $7 price target by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100